Navigation Links
EGT Transfers cGMP Vector for Gene Therapy Trial
Date:7/29/2011

CHICAGO, July 29, 2011 /PRNewswire/ -- Errant Gene Therapeutics, LLC ("EGT"), a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center ("MSKCC"). TNS 9.55.3  developed by EGT pursuant to an exclusive license agreement with Sloan Kettering Institute (SKI), will be used for MSKCC's upcoming beta Thalassemia human clinical trial. The trial protocol provides for the "in vitro" treatment of beta-thalassemia patients, offering the prospect for a cure for a chronic condition which would otherwise subject the patient to early death without incurring life-long regular blood transfusions and chelation therapy.

A new definitive agreement between EGT and SKI provides for MSKCC to lead the clinical trials and arrange for drug development partnerships for the treatment of beta-Thalassemia and Sickle Cell Disease, two of the worlds most prevalent and devastating hereditary blood conditions.  

EGT continues its decade's long commitment to cure beta-Thalassemia, also called Cooley's Anemia, through dedicated outreach to patient and research communities around the world. Pat Girondi, EGT founder and CEO, stated, "the pioneering research of SKI's Sadelain team is positioned to deliver the safest and most effective cure for the many millions of patients whose hopes and prayers we have honored with our total dedication." EGT received protocol approval for the upcoming trials by unanimous vote of the Recombinant DNA Advisory Committee of the NIH in 2007, and was granted orphan drug designation by both the FDA and the EMEA. The clinical trial is expected to commence in the fourth quarter of 2011.

Sam Salman, EGT's president said that with "MSKCC and SKI taking the lead in the clinical and developmental activities for TNS 9.55.3, EGT will be able to further progress its pre-clinical programs for its novel drug cancer therapies targeting chronic hormone refractory cancers."  

About Errant Gene Therapeutics, LLC

Errant Gene Therapeutics ("EGT") is a privately held biopharmaceutical company established in 2003. In addition to its ongoing support of gene therapy for the cure of beta-thalassemia and Sickle Cell Anemia, EGT is a pioneer in the emerging field of epigenetics focused on the treatment of deadly hormone  refractory cancers using its patented portfolio of small molecule histone deacetylases inhibitors (HDACi). EGT's lead HDACi, CG-1521, targets Inflammatory Breast Cancer and Hormone Refractory Prostate Cancer.

For more information about EGT and its programs, please visit www.errantgene.com.


'/>"/>
SOURCE Errant Gene Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary
2. Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotlands Five Cancer Centers
3. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
4. Arkansas Researcher is Exploring MR-Guided Focused Ultrasound as an Adjuvant Therapy to Radiation
5. Mail-Order Pharmacy for New Statin Prescriptions Achieve Better Cholesterol Control in First 3-15 Months of Therapy
6. Provent® Sleep Apnea Therapy Now Available in India
7. OrbusNeichs Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
8. New Release of Elektas Monaco Treatment Planning System Prepares Software for Stereotactic Radiation Therapy
9. Latest Releases of Elektas XiO Planning and Focal Contouring Systems Designed to Increase Efficiency in Planning Therapy for Patients with Cancer
10. Dehaier Opens First Oxygen Filling Facility and First Service Center for Home Oxygen Therapy Service in Beijing
11. PhotoMedexs Itching to Win Contest Offers Free Phototherapy Treatments With the XTRAC Laser to Deserving Psoriasis Patients Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):